Jul 08, 2025 09:31 JST

Source: Eisai

Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment

TOKYO, July 8, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it has been selected for the highest rating of “Supplier Engagement Leader” in the Supplier Engagement Rating by the global environmental non-profit organization CDP.(1)

The Supplier Engagement Assessment evaluates how effectively companies are working with suppliers to address climate change issues. In its responses to the CDP Climate Change Questionnaire on 'Governance', 'Targets', 'Scope 3 emissions(2)' and 'Value chain engagement', Eisai’s efforts to engage with suppliers were highly regarded, leading to this selection. To conduct environmentally conscious business activities throughout our entire supply chain, Eisai asks business partners to comply with the “Eisai Global Code of Conduct for Business Partners(3)” which clearly states Eisai’s requirement for environmental conservation. Collaboration with suppliers is also strengthened by conducting sustainability assessments of partners and providing feedback on the results.

Eisai identifies “Business activities with consideration for the global environment” as one of its material issues. Based on the “Eisai Network Companies Environmental Protection Policy”, Eisai is promoting responses to climate change as key environmental activities across the group. Eisai is working towards the realization of a decarbonized society, including receiving approval for the SBT 1.5°C target from the Science Based Targets (SBT) Initiative in FY2023, and participating in the Japan Climate Initiative (JCI)Race to Zero Circle, which calls for achieving net zero by 2050.(4)

Please refer to Eisai’s website for more detailed information about its environmental activities.

The preservation of the global environment is essential for realizing Eisai’s corporate concept of human health care (hhc). Eisai will contribute to empowering people to “realize their fullest lives” through our climate change initiatives.

(1)A non-profit organization headquartered in the UK. The organization operates the world’s only independent environmental information disclosure system.
(2)Indirect greenhouse gas emissions across the entire corporate value chain
(3)Please refer here for further details
(4)Please refer to the following news release for details. EISAI TO BOOST INITIATIVES ON GREENHOUSE GASREDUCTION, AIMING TO ACHIEVE NET ZERO BY 2050
https:/www.eisai.com/news/2024/news202412.html

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

 

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
 
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
 
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
 
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
 
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
 
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 08 2025 16:49 JST
 
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 04 2025 09:56 JST
 
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
September 03 2025 10:32 JST
 
More Press release >>

Latest Press Release


More Latest Release >>